GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » 3-Year Sortino Ratio

GLSI (Greenwich LifeSciences) 3-Year Sortino Ratio : 0.60 (As of Jul. 23, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences 3-Year Sortino Ratio?

The 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. As of today (2025-07-23), Greenwich LifeSciences's 3-Year Sortino Ratio is 0.60.


Competitive Comparison of Greenwich LifeSciences's 3-Year Sortino Ratio

For the Biotechnology subindustry, Greenwich LifeSciences's 3-Year Sortino Ratio, along with its competitors' market caps and 3-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenwich LifeSciences's 3-Year Sortino Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's 3-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's 3-Year Sortino Ratio falls into.


;
;

Greenwich LifeSciences 3-Year Sortino Ratio Calculation

The 3-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last three year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 3-Year Sortino Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past three year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.


Greenwich LifeSciences  (NAS:GLSI) 3-Year Sortino Ratio Explanation

The 3-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past three year. It is calculated as the annualized result of the average three-year monthly excess returns divided by the standard deviation of negative returns in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


Greenwich LifeSciences 3-Year Sortino Ratio Related Terms

Thank you for viewing the detailed overview of Greenwich LifeSciences's 3-Year Sortino Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenwich LifeSciences Business Description

Traded in Other Exchanges
N/A
Address
3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Executives
Snehal Patel director, officer: CHIEF EXECUTIVE OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson officer: VPC AND REGULATORY AFFAIRS 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty director, officer: CHIEF MEDICAL OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams director 2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel 10 percent owner 3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel 10 percent owner 50726 LAKESIDE DRIVE, GRANGER IN 46530